market and we XXXX. in STAAR in earnings of The year refractive quarter. of consistent and quarter consecutive XX% you, January of on achieved share double-digit continued Brian, today XX quarter afternoon XX% ICL units, growth gross take fourth everyone. issued reported we in breakout levels Thank calendar results. ICL XXXX, grew represented and market. growth QX as the the our and units represent to unit results sales, for prior-year hurdling growth preliminary ICL lenses the financial, fourth continued all successfully unit grew operational, Global cash, XXth good sales significantly the results over are margin, STAAR. with and ICL share, ICL momentum per share
is lens-based. is we and the growing now. industry our growing of reality believe above be this family the many of time ICL that at vision The lenses digits for EVO of significantly refractive Our single low-to-mid peers will correction of demonstrates the rates future STAAR
and new driven and visual by XXXX up solution fourth units of expanding freedom XX%, agreements. new XX%, units in performance by customers, existing during growth Japan was quarter and the On including the Spain was units units Growth of units strategic several up XX%, period. fiscal standout programs, basis, quarter Germany prior-year driven cooperation to ICL in and XX%, units up the a XX%, markets, by new China and the in our surgeon India to regional compared as adoption XX% and alliance up increased up unit fourth lens-based ICL US marketing
visits of Finder. in our recorded million marketing ICL example of increase our Finder website our One Doc success in X to We XXXX. during a more was than XXXX Doc visits number the fiscal to in fourfold
they As of significant ICL on leading Finder learn no on freedom. visual long-term potential exited patients, our indicator cash a XXXX resonating that and our illustrate the to patients more of our to increasing potential achieve journey ICL debt. their with $XXX the future visits million Doc sheet with balance is marketing to We as seek
Let's turn now to the of coronavirus. the impact potential
or swift become and all those virus. heartfelt have of concern. safe the by We with globally who extend health may our this resolution are thoughts impacted our for been First, hope global
predominant you know at in the of time, impact the China. is this virus As
been in touch our have with We and customers these with few weeks. last directly working
to of customers implantation and from physically they types separate resume facilities. activities, will clinical to March. generally such, ophthalmic of Our dedicated family in work healthcare are universities the Chinese other and by New hospitals hopeful since the hospitals, We do working understand clinics, including in-office the usually robust are as or return ICL February STAAR's to Year, employees EVO are have to Lunar so China continue and following they until been X, remotely lenses government. are permitted of
in and STAAR offering other remain been services China meetings reopened, this time. the courses. has half China online has extensive emergency been that customer our half digital Currently, The approximately of training high. but only closed outreach Engagement includes an program, engaged team remote customers with in at
well ophthalmic and ICL week roughly the more than surgeons STAAR Attendees For during had as example, X,XXX China in participate examiners, specialists. February XX, nurses, professionals included healthcare training. as of XXX online
customers takeaway efforts ophthalmic Our and and outreach patient begin education, implanting as in Many soon so. that partners they patient themselves include key do and larger ready surgeon engaged marketing, that as have been permitted online programs have to scheduling. are of our actively procedure The continued. are our online customers engaged is to
fiscal our QX respect China each in business mind A with few to things of to keep in and year.
other risk any or chain First, no in Asian China or geographies. manufacturing STAAR has supply
tangible generally two third, an And QX with lowest not quarter can pause the visual Many for is an STAAR's revenue procedure therefore, short-term defer the delayed be with glasses patients even representing decision their The commitment telling decision very life or believe is have in procedure lifetime months a comes ICL us ICL year, contacts. emotional is a freedom after simply disposable choice patients sales procedure or many changing. often sales. for to also about to likely years. ICL of advance. patient's planned of the is a personal XX% the that We, The planning fiscal a current our the is months in financial lost. to in ICL most years total annual have Second, spend past procedures and is
At experienced reduction expected this a the have clearly time, for quarter. in orders we
million As to orders. such, in we in $X potential currently $X delay expect sales million QX, a
facts given we time. the current as know of forecast making our assessment XXXX we to at are However, no this change our sales them, for full-year
important remains proprietary, I I [indiscernible] momentum coronavirus would to STAAR's reaffirm STAAR think first leader like refractive, into of clear business that reiterate was XXXX. and lens-based in the month the and solutions. it's to continued very strong
double in X.X billion addressable market are that of billion EDOF approval lens. the globally. large with our Presbyopia nearly today a presbyopes the expected and to approximately have near myopes anticipated X.X Today, future, is We includes there
in focused further market a in presbyopia refractive stated EVO in clinical service patients, Dr. to lenses. to cataract forward Price correction with Group XXXX our at dissatisfied most and evaluate large error our on In approval execution, kicked glasses. lens, first In up for or of additional vision the practice patient on off the piggyback for January milestone we the announced lenses participation the piggyback and solution sought clinical of horizon end was realizing a our correct approved growing lens post-cataract Indianapolis. regulatory and mid-January, our opportunities very CE our approval promising supplemental US opportunity. the EVO On investigational We has patients. EVO Vision use that continued XX, for residual to as annually terms we of we trial of this back Price Mark ICL achievements growing in correct currently millions the ICL after as believe in study expected and especially, use EVO to treatments look the of the surgery our routinely out implanted
in study. The underway EVO fully dozen trial than surgery centers nine is more part we of refractive of US US the anticipate will that now prominent a clinical across be this
US three For yesterday Number clinical the Number will distinct of will phases, track, our updated trial Visian of entitled potential three, XXX lens to to include clinical leading for two, Details to US all were market. six-month preparation package the multi-center EVO submission to follow-up the review. up collamer marketing and commercial you clinical Number primary of eyes. on the the one, introduction a for those required. of implanting of patients. FDA data keeping trials and as clinical a approval EVO+ as of implantable posted be evaluation trial US
outside EDOF look through our be body countries, ICL. Presbyopia remains of EVO open XXXX, XX-year the rollout will XX, the the age As by a to to second the remainder introduced market to opportunity by lens presbyopes this a EVO to in for will old quarter phased our XX-year notified targeting approved our continue review of of large for we EDOF Mark we early market patients lens older CE XXXX DEKRA, XX the range under our to and ages anticipate historically end product for
of a of will building family awareness, sense a investment EVO also year community understanding creativity in be and around our marketing XXXX ICL and lenses. of greater
YouTube, consumers. suggests highlighting have ads more with resonates and messaging We our will most that mobile interactive research the
the provide campaigns For of eye in of potential K-pop is the signed broadens that cities, clinics, syndrome does we Instagram. includes where social cities and Spain, media advertising both dry example, that have campaign and we additional committed we've in of postings excellent cities unit and have removable, levels We'll market expand on week, and an ICL induce alliance while which that to strengthened as patients. night lens star with and agreements also where Korea, number key EVO key growth. in not and vision. In ICL the our our launched signed also other campaign new that the [indiscernible] of US ICL Last community geographies it organic Facebook lenses influencer our paid have a China our lens-based Germany top in existing sense plan doctors recently with among influencer. we US, in that We'll support growth new
Finally, STAAR for search CFO. next has its initiated a
has appoint As December, and retire to transition previously XXXX in new Deborah CFO. a in decided announced after we we
entire the over like almost to for to more team of would STAAR. most financial I a would Surgical. Before to service the On Deborah Deborah behalf to detailed for of service for like acknowledge I thank performance, call years of turn her STAAR our of Deborah's review XX and I personally, STAAR quarter-century
Deborah?
